More stories

Psyence Group Completes Export of Psilocybin Mushrooms to Portugal

TORONTO, Sept. 29, 2022 (GLOBE NEWSWIRE) — Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”) is pleased to announce that...

Numinus to Participate in the Cantor Neurology & Psychiatry Conference on October 6-7, 2022

VANCOUVER, BC, Sept. 29, 2022 /PRNewswire/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) ( OTCQX: NUMIF), a mental health care company...

PT360 – Stephanie Wang – Kanna: Love and Wholeness Through Nature’s Alternative to MDMA

In this episode, Joe Moore interviews Stephanie Wang: Founder and CEO of KA! Empathogenics, which has created the first-ever empathogenic supplement chew with the...

PharmaTher Provides Business Highlights and Releases Audited Annual Financials for Fiscal Year Ended May...

Nearly $12 million in cash and investment Fully funded for the Company’s development programs, including ketamine injection and infusion products, ketamine microneedle patch and...

Reunion Neuroscience Inc. Appoints Greg Mayes as President and Chief Executive Officer

TORONTO, Sept. 28, 2022 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) (“Reunion” or the “Company”), a leader in novel psychedelic drug...

MindMed Announces Pricing of Public Offering of Common Shares and Warrants

NEW YORK, Sept. 27, 2022 /PRNewswire/ — Mind Medicine (MindMed) Inc. (“MindMed”) (NASDAQ: MNMD) (NEO: MMED), a clinical stage biopharmaceutical company developing novel products...

Mindset Pharma Provides Strategic Intellectual Property License to Cybin

TORONTO, Sept. 27, 2022 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset”), a drug discovery company developing novel, optimized,...

Silo Pharma Announces Uplisting to Nasdaq Capital Market and Pricing of $5 Million Public...

ENGLEWOOD CLIFFS, NJ , Sept. 27, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (formerly OTCQB: SILO), a developmental stage biopharmaceutical company focused...

MindMed Announces Proposed Public Offering of Common Shares

NEW YORK, Sept. 27, 2022 /PRNewswire/ — Mind Medicine (MindMed) Inc. (“MindMed”) ( Nasdaq: MNMD) (NEO: MMED), a clinical stage biopharmaceutical company developing novel...

BetterLife Files Comprehensive Patent for BETR-001 and Other LSD Derivatives

VANCOUVER, British Columbia, Sept. 27, 2022 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU),...

atai Life Sciences Announces Initiation of Phase 1 Trial for its MDMA Derivative, EMP-01

– atai’s wholly owned subsidiary, EmpathBio, has received Medsafe central regulatory and The Health and Disability Ethics Committees (HDEC) ethics approvals to initiate a...

PT359 – Sawyer Hurwitz – Art, Philosophy, Sexuality, and “Psychedelics Tonight”

In this episode, Joe Moore interviews Sawyer Hurwitz: filmmaker, producer, editor, and augmented reality collage artist who releases animated art under the name, “Psychotronic...

Most popular